Recent pages

Company Name

G/Genentech (DNA)

Edit
page

New
page

Print
page

This page was last modified over a year ago by Sysop

Genentech (DNA)

This is an EDITABLE stock research wiki. You can contribute by clicking on the EDIT PAGE link above or on the page icons that appear when you roll over one of the category subtitles below.

From 1

1. Company Information:
2. Company Overview:

2.1. Company Products/Services/Markets:
2.2. Strategy:
2.3. Competitors:
2.4. Industry Trends and News:
2.5. Acquisitions, Divestitures, Major Transactions, Spin-offs :
2.6. Management – Pros & Cons, Changes:

5.1. Buy Rationale:
5.2. Sell Rationale:

6. Projected Financials:
7. Discussion:
8. Footnotes:
9. News:
10. See Also (links to blogs, forums, external sources, etc...):

Company Information:

Company Address:

1 DNA Way

South San Francisc, CA 94080-4990

Company’s Web Address: http://www.gene.com/

Industry Sector:

Fiscal Year:

Dividend:

Note: this section is not editable. Please click here to report any inaccuracies.

Shares Outstanding: 1,100,000,000
Market Capitalization: Updating...

Income Statements
Click for: Annual Income Statement
Click for: Quarterly Income Statement

Balance Sheets
Click for: Annual Balance Sheet
Click for: Quarterly Balance Sheet

Cash Flow Statements
Click for: Annual Cash Flow Statement
Click for: Quarterly Cash Flow Statement

SEC Filings
Click for: Form 10-Ks
Click for: Form 10-Qs
Click for: Annual Proxy Statements
Link to SEC filings search: http://www.sec.gov/cgi-bin/srch-edgar

Company Overview:

Note: this section is not editable.

Genentech, Inc. (DNA) is one of the world's largest biotechnology companies. It currently manufactures and sells over a dozen biotechnology products in the U.S., and licenses additional products to other companies to earn royalties. The company's leading products are Rituxan (for non-Hodgkin's lymphoma, or NHL), Avastin (for colorectal cancer), Herceptin (for breast cancer), and Lucentis (for age-related macular degeneration). Sales from growth hormones, cardiovascular products, Pulmozyme (for cystic fibrosis), Xolair (asthma), Raptiva (psoriasis), and Tarceva (lung cancer) also contribute to revenues. The company possesses an impressive oncology pipeline, with additional label potential for both Avastin and Tarceva. Additionally, the company has an enormous pipeline with over a dozen key development collaborations. Product sales growth, primarily driven by Avastin, Lucentis, and Tarceva, should lead to impressive revenue growth the next several years. The company, which is based in San Francisco, CA, employs roughly 10,530 people. Roche Holdings currently has a 56% stake in Genentech.

Read full report on Genentech, Inc

Company overview provided by

Company Products/Services/Markets:

Enter Company Products/Services Here

Strategy:

Describe Key Aspects of Company's Strategy Here

Competitors:

Enter Competitors Here

Industry Trends and News:

Enter Industry Trends and News Here

Acquisitions, Divestitures, Major Transactions, Spin-offs :

Enter Acquisitions, Divestiures, Major Transactions, Spin-offs Here

Management – Pros & Cons, Changes:

Enter Management - Pros & Cons, Changes Here

Financial Analysis:

Enter Financial Analysis Here

Valuation:

Enter Valuation Analysis and Valuation Ratios Here

	2007	2006	2005
Price/Earnings
Price/EBITDA
Price/Pre-tax Income
Price/Revenue

Investment Rationale:

Buy Rationale:

Enter Buy Rationale Here

Sell Rationale:

Enter Sell Rationale Here

Projected Financials:

Income Statement: (Paste Here)

Balance Sheet: (Paste Here)

Cash Flow Statement: (Paste Here)

Financial Ratios: (Paste Here)

Other: (Paste Here)

Discussion:

This area is for debates regarding different recommendations for this stock.

Footnotes:

News:

Yahoo! Finance Blog
Add this Facebook Y! application to your profile In a tough market, I get by with a little help from my friends… The turbulence and wild swings of the world’s financial markets have been enough to make even the sturdiest of investors a little queasy as of late. If you haven’t already, you will likely lose most of your appetite for risk as [...]
Yahoo! Finance Goes Global At midnight on Tuesday, something great happened. Something BRILLIANT. Yahoo! Finance launched 15 new pages across Europe to some great user feedback. But it wasn’t just the pages that we should be rightly proud of –- it’s the united Global Yahoo! Finance team behind it; the upgraded processes and infrastructure behind the design. Engineers, [...]
Introducing Ticker Tape on the Quotes Pages We are excited to add a popular new feature to the top of all our quotes pages. Now you have faster and easier access to stocks you care most about. The new ticker tape, prominently placed, displays the most recent quotes you last looked at. This is the same useful functionality we offer [...]
Getting the most out of the Interactive Chart If you’ve clicked the thumbnail chart — or a time period link below it — on our quote page, you’ve likely visited our Interactive Chart. The Interactive Chart is a relatively new addition to Yahoo! Finance; it became generally available in April. There are several things you can do on the Interactive Chart that you [...]
Real-Time ECN Quotes Are Now Available on Multi-Quote and Portfolios Pages! Thanks to everyone for the great feedback on our recent real-time features on Yahoo! Finance. We know this is information you value, so today we’re pleased to build on our real-time features with the addition of Real-Time ECN views in multi-quote and portfolio pages on Yahoo! Finance. With the markets being volatile and earnings right around [...]